CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 179 enrolled
Drug / intervention
Mazdutide +1 moredrug
Likely dose
Not stated in record
Key inclusion· 2
  • ✓BMI ≥27 kg/m²
  • ✓Males and females who agree to abide by reproductive and contraceptive requirements
Key exclusion· 10
  • ✕Prior diagnosis of diabetes mellitus (type 2 or rare forms), except gestational diabetes
  • ✕Major cardiovascular event (MI, stroke, unstable angina, CHF hospitalization) within 6 months prior to screening
  • ✕History of NYHA Functional Classification I-IV CHF
  • ✕Uncontrolled hypertension (BP >140/90 mmHg)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06124807
NCT06124807Phase 2Completed
CompareCT.gov

A Phase 2, Parallel-Group, Double-Blind, 4-Arm Study to Investigate Weight Management With LY3305677 Compared With Placebo and in Adult Participants With Obesity or Overweight

Eli Lilly and Company·interventional·Posted Nov 9, 2023·Updated Apr 21, 2026

In Brief

A Phase 2 clinical trial evaluating Mazdutide and Placebo for Obesity and Overweight and Obesity. Completed, enrolled 179 participants across 29 sites.

Detailed Summary

The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with Mazdutide compared with placebo and in adult participants with obesity or overweight. The study will last about 62 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Overweight and Obesity
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedNov 9, 2023
Enrollment StartNov 17, 2023
Primary CompletionJan 22, 2025
Study CompletionJul 9, 2025
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 2.6 years ago

Interventions

Mazdutidedrug

Administered subcutaneous (SC)

Placebodrug

Administered SC